Summary: Dupilumab is currently the only monoclonal antibody reg-istered in Poland for the treatment of severe atopic dermatitis (AD). Clinical data show the high effectiveness of this drug both in terms of clinical improvement and patients’ quality of life. It is considered safe in terms of biochemical and hematological parameters. The available literature draws attention to the side effects of dry eye syndrome, conjunctivitis, and erythema and rash of the face and neck. In the near future, it can be expected that the preparation may be included in the drug program in Poland, which may contribute to better and more effective treatment of the most severe patients with AD.